PMID- 38153858 OWN - NLM STAT- Publisher LR - 20240119 IS - 1386-6346 (Print) IS - 1386-6346 (Linking) DP - 2023 Dec 28 TI - Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real-world study. LID - 10.1111/hepr.14007 [doi] AB - AIM: The study was conducted to evaluate the feasibility and safety profile of hepatic arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin (HAIC-FOLFOX) as an alternative therapeutic choice for patients with advanced hepatocellular carcinoma (HCC) that is refractory to systemic treatment including immune checkpoint blockades or molecular targeting agents. METHODS: Two hundred and forty five consecutive patients with advanced HCC who received HAIC-FOLFOX treatment after systemic treatment failure were retrospectively reviewed in six institutions and their survival, tumor response, and tolerance were assessed. RESULTS: The median overall survival (OS) and progression-free survival of the 209 included participants were 10.5 months (95% confidence interval [CI], 8.1-12.9) and 6.0 months (95% CI, 5.1-6.9), respectively. According to Response Evaluation Criteria in Solid Tumors 1.1 criteria, the objective response rate was 21.1%, and the disease control rate was 64.6%. Multivariate analysis of risk factors of OS were albumin-bilirubin grade (2 and 3 vs. 1, hazard ratio [HR] 1.57; 95% CI, 1.05-2.34; p = 0.028), tumor number (>3 vs. 1-3, HR 2.18; 95% CI, 1.10-4.34; p = 0.026), extrahepatic spread (present vs. absent, HR 1.61, 95% CI, 1.06-2.45; p = 0.027), synchronous systemic treatment (present vs. absent, HR 0.55, 95% CI, 0.37-0.83; p = 0.004) and treatment response (responder vs. nonresponder, HR 0.30, 95% CI, 0.17-0.53; p < 0.001). Grade 3-4 adverse events (AEs) occurred in 59 (28.2%) HCC patients. All AEs were manageable, and deaths related to hepatic artery infusion chemotherapy treatment were not observed. CONCLUSIONS: Our findings support the effectiveness and safety of HAIC-FOLFOX treatment for patients with advanced HCC who have failed systemic treatment. CI - (c) 2023 Japan Society of Hepatology. FAU - Yi, Jun-Zhe AU - Yi JZ AD - Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Zhu, Zhi-Jian AU - Zhu ZJ AD - Department of Oncology, Ganzhou Cancer Hospital, Ganzhou, China. FAU - Liu, Gong-Wei AU - Liu GW AD - Department of Oncology, The Sixth Affiliated Hospital of Guangxi Medical University, Yulin, China. FAU - Zhang, Yi-Min AU - Zhang YM AD - Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. FAU - Xu, Jie AU - Xu J AD - Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Wu, Xin-Tong AU - Wu XT AD - Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. FAU - Ding, Ke AU - Ding K AD - Department of Oncology, Jiangmen Affiliated Hospital of Chinese Medicine, Jinan University, Jiangmen, China. FAU - Liu, Jian-Chao AU - Liu JC AD - Department of Oncology, Beihai People's Hospital, Guangxi Medical University, Beihai, China. FAU - Zhang, Ke-Fei AU - Zhang KF AD - Department of Oncology, The Air Force Hospital of Southern Theater Command, Guangzhou, China. FAU - Jiang, Xiong-Ying AU - Jiang XY AD - Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Chen, Qi-Feng AU - Chen QF AD - Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. AD - Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. FAU - Hu, Yue AU - Hu Y AD - Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Chen, Song AU - Chen S AD - Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Zhong, Sui-Xing AU - Zhong SX AD - Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Wang, Jiong-Liang AU - Wang JL AD - Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center, Guangzhou, China. FAU - Lyu, Ning AU - Lyu N AD - Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. AD - Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. FAU - Zhao, Ming AU - Zhao M AUID- ORCID: 0000-0002-1025-8895 AD - Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China. AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. AD - Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. LA - eng GR - 82372061/National Natural Science Foundation of China/ GR - 82072022/National Natural Science Foundation of China/ GR - 2021A1515010403/Basic and Applied Basic Research Foundation of Guangdong Province/ PT - Journal Article DEP - 20231228 PL - Netherlands TA - Hepatol Res JT - Hepatology research : the official journal of the Japan Society of Hepatology JID - 9711801 OTO - NOTNLM OT - hepatic arterial infusion chemotherapy OT - hepatocellular carcinoma OT - immune checkpoint inhibitor OT - molecular targeting agent OT - systemic treatment failure EDAT- 2023/12/28 18:42 MHDA- 2023/12/28 18:42 CRDT- 2023/12/28 13:02 PHST- 2023/12/12 00:00 [revised] PHST- 2023/10/17 00:00 [received] PHST- 2023/12/23 00:00 [accepted] PHST- 2023/12/28 18:42 [pubmed] PHST- 2023/12/28 18:42 [medline] PHST- 2023/12/28 13:02 [entrez] AID - 10.1111/hepr.14007 [doi] PST - aheadofprint SO - Hepatol Res. 2023 Dec 28. doi: 10.1111/hepr.14007.